AUSTIN, Tex.—Multiplex system developer Luminex and Copenhagen-based Exiqon A/S announced an agreement to co-develop and commercialize microRNA products. The deal will see Exiqon combine its Locked Nucleic Acid (LNA) technology with Luminex's xMAP technology on behalf of the Luminex Bioscience Group. Financial details were not disclosed.

"Luminex xMAP instruments hold a significant share of detection platforms in the life sciences industry in both the research and clinical settings," said Lars Kongsbak, Exiqon president and CEO. "This collaboration will ensure our highly specific microRNA detection chemistries are broadly available to this market segment, which is an important strategic accomplishment for Exiqon."